Literature DB >> 15070095

Differential adhesion of normal and inflamed rat colonic mucosa by charged liposomes.

Tareq Taha Jubeh1, Yechezkel Barenholz, Abraham Rubinstein.   

Abstract

PURPOSE: To study the adhesion properties of charged liposomes to the healthy and inflamed (colitis-induced) rat intestinal epithelium.
METHODS: Neutral, positively charged, and negatively charged liposomes were prepared and tagged. The cationic or anionic liposomes contained increasing amounts (13, 22, or 36 mol%) of either the cationic lipid dimethyl-dioctadecylammoniumbromide (DODAB) or the anionic lipid 1,2-dimyristoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] (DSPG). Colitis was induced in rats by DNBS. Adhesion of the various types of liposomes was assessed in rat colon sacs. The effects of charge type, charge density (mol%), liposome size, and incubation time on the adhesion of the liposomes were compared in the inflamed and healthy epithelial tissues.
RESULTS: Three times as many cationic liposomes adhered to the healthy colonic mucosa than neutral or anionic liposomes. However, anionic liposome adherence to the inflamed colonic mucosa was 2-fold that of either neutral or cationic liposomes (a finding that was verified by charged-dyes studies). Adherence was directly correlated with charge density. An inverse correlation was identified between cationic liposome size and healthy tissue adherence in short incubation periods. The adherence of cationic liposomes, which was also found to be time-dependent, decreased in healthy mucosa in the presence of high concentrations of aqueous Mg2+ rinse.
CONCLUSIONS: Anionic liposomes could be useful for the topical delivery of anti-inflammatory drugs in inflammatory bowel disease therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15070095     DOI: 10.1023/B:PHAM.0000019298.29561.cd

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  33 in total

1.  Lectin-mediated drug delivery: the second generation of bioadhesives.

Authors:  C M Lehr
Journal:  J Control Release       Date:  2000-03-01       Impact factor: 9.776

Review 2.  Chitosan for mucosal vaccination.

Authors:  I M van der Lubben; J C Verhoef; G Borchard; H E Junginger
Journal:  Adv Drug Deliv Rev       Date:  2001-11-05       Impact factor: 15.470

Review 3.  Novel applications of liposomes.

Authors:  D D Lasic
Journal:  Trends Biotechnol       Date:  1998-07       Impact factor: 19.536

Review 4.  Inflammatory bowel disease: new insights into pathogenesis and treatment.

Authors:  S Ardizzone; G Bianchi Porro
Journal:  J Intern Med       Date:  2002-12       Impact factor: 8.989

Review 5.  Drug targeting by surface cationization.

Authors:  S Blau; T T Jubeh; S M Haupt; A Rubinstein
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  2000       Impact factor: 4.889

6.  Adsorption of cationized bovine serum albumin onto epithelial crypt fractions of the rat colon.

Authors:  S Blau; N Levin; B Schwartz; A Rubinstein
Journal:  J Pharm Sci       Date:  2001-10       Impact factor: 3.534

7.  Bioadhesive, collagen-modified liposomes: molecular and cellular level studies on the kinetics of drug release and on binding to cell monolayers.

Authors:  N Yerushalmi; R Margalit
Journal:  Biochim Biophys Acta       Date:  1994-01-03

8.  Polysaccharide coated liposomes for oral immunization--development and characterization.

Authors:  N Venkatesan; S P Vyas
Journal:  Int J Pharm       Date:  2000-08-10       Impact factor: 5.875

9.  A new method for the quantification of neutrophil and eosinophil cationic proteins in feces: establishment of normal levels and clinical application in patients with inflammatory bowel disease.

Authors:  Christer G B Peterson; Elisabeth Eklund; Yesuf Taha; Yngve Raab; Marie Carlson
Journal:  Am J Gastroenterol       Date:  2002-07       Impact factor: 10.864

10.  Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models.

Authors:  J E Krawisz; P Sharon; W F Stenson
Journal:  Gastroenterology       Date:  1984-12       Impact factor: 22.682

View more
  22 in total

1.  Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis.

Authors:  Bo Xiao; Zhigang Xu; Emilie Viennois; Yuchen Zhang; Zhan Zhang; Mingzhen Zhang; Moon Kwon Han; Yuejun Kang; Didier Merlin
Journal:  Mol Ther       Date:  2017-01-28       Impact factor: 11.454

Review 2.  Nanomedicines in gastroenterology and hepatology.

Authors:  Alf Lamprecht
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-03-10       Impact factor: 46.802

Review 3.  Deciphering the pathophysiology of irritable bowel syndrome and functional gastrointestinal disorders-an alternative model for pathogenesis: cytokine controlled transepithelial multi-feedback loop.

Authors:  Ricky McCullough; Jeremiah McCullough
Journal:  Transl Gastroenterol Hepatol       Date:  2017-03-17

Review 4.  Nanoparticles for oral delivery: Design, evaluation and state-of-the-art.

Authors:  Abhijit A Date; Justin Hanes; Laura M Ensign
Journal:  J Control Release       Date:  2016-06-09       Impact factor: 9.776

5.  Nanoparticulate Drug Delivery Systems Targeting Inflammation for Treatment of Inflammatory Bowel Disease.

Authors:  Sufeng Zhang; Robert Langer; Giovanni Traverso
Journal:  Nano Today       Date:  2017-10-09       Impact factor: 20.722

6.  Liposomal formulations of inflammatory bowel disease drugs: local versus systemic drug delivery in a rat model.

Authors:  Filippos Kesisoglou; Simon Yuji Zhou; Susan Niemiec; Jordan Wing Lee; Ellen M Zimmermann; David Fleisher
Journal:  Pharm Res       Date:  2005-08-03       Impact factor: 4.200

Review 7.  Targeted drug-delivery approaches by nanoparticulate carriers in the therapy of inflammatory diseases.

Authors:  Wiebke Ulbrich; Alf Lamprecht
Journal:  J R Soc Interface       Date:  2009-11-25       Impact factor: 4.118

Review 8.  Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues.

Authors:  Samuel K Lai; Ying-Ying Wang; Justin Hanes
Journal:  Adv Drug Deliv Rev       Date:  2008-12-13       Impact factor: 15.470

9.  An inflammation-targeting hydrogel for local drug delivery in inflammatory bowel disease.

Authors:  Sufeng Zhang; Joerg Ermann; Marc D Succi; Allen Zhou; Matthew J Hamilton; Bonnie Cao; Joshua R Korzenik; Jonathan N Glickman; Praveen K Vemula; Laurie H Glimcher; Giovanni Traverso; Robert Langer; Jeffrey M Karp
Journal:  Sci Transl Med       Date:  2015-08-12       Impact factor: 17.956

Review 10.  Current Strategies and Potential Prospects of Nanomedicine-Mediated Therapy in Inflammatory Bowel Disease.

Authors:  Fengqian Chen; Qi Liu; Yang Xiong; Li Xu
Journal:  Int J Nanomedicine       Date:  2021-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.